Personalized medicine: Taubman Scholar Dr. Arul Chinnaiyan weighs in on cancer treatment potential

Dr. Arul Chinnaiyan, director of the Michigan Center for Translational Pathology and a Taubman Scholar, was quoted on Feb. 16 in a Detroit News article about the prospects for personalized cancer treatment: 

 

(Dr. Chinnaiyan) is working to develop new molecular tests and therapeutics for human diseases, with a focus on cancer.

Not all patients respond to conventional treatments, so when they reach advanced stages of cancer they are enrolled in a clinical sequencing program.

Since 2011, U-M has sequenced 150 adult patients and 15 children, Chinnaiyan said. The six-week process sequences the cancer tumor along with normal tissue and compares them.

"We're trying to figure out what mutations have occurred in the patient's tumor relative to the normal genome," Chinnaiyan said. "We analyze the data in the context of the mutation to see if there are any clinical trials that might be appropriate or approved drugs that might work."

A small percentage of patients fit the criteria for clinical trials or approved drugs, and an even smaller percentage will respond. But early research has offered some success stories that will be published in academic journals in the near future.

"Patients who have failed conventional therapies are looking for options," Chinnaiyan said.

Click here to read the complete article.



 


Help Us Make A Difference. Make A Donation That Could Save Lives.

Make A Gift

Connect/
Share/
follow/

Follow Us / Friend Us

Discovery-driven research that matters

phallodin

Taubman Scholar Dr. Charles Burant tests promising diabetes drug

TAK-875, a new treatment for type 2 diabetes, improves blood sugar control and is equally effective as glimepiride, but has a significantly lower risk of creating a dangerous drop in blood sugar, called hypoglycemia, according to a new study.

Read more

Taubman Institute leaders make the case for more doctor-scientist funding

 

The prestigious "Academic Medicine" journal has just published a new article authored by Taubman Institute senior management and Detroit-area attorney Scott Roberts.

The article explores the problematic gap between bench research and clinical application of new treatments or cures. 

Read more


Help Us Make A Difference. Make A Gift.

Leaders from the realms of business, academia and the community help to refine the Taubman Institute's vision, to monitor progress and to provide support, advice and counsel.

Meet the Leadership Advisory Board

Meet the Scientific Advisory Board

About Taubman Institute Video

In this video feature, Taubman Scholars explain why funding for high-risk research is so important to their work and to the discovery of promising cures and treatments.  

 

Stem cell surgery targets ALS Video

Patients glean hope from trial’s progress but wish it were faster

 

video-emerging-scholars-programDonors pitch in to keep brilliant science minds at U-M Video

Emerging Scholars program connects promising M.D.-researchers with philanthropists